Citigroup’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $38.7M | Buy |
+200,000
| New | +$38.6M | 0.02% | 742 |
|
|
2025
Q4 | – | Sell |
-50,000
| Closed | -$7.67M | – | 6068 |
|
|
2025
Q3 | $7.67M | Buy |
+50,000
| New | +$7.57M | ﹤0.01% | 1675 |
|
|
2025
Q1 | – | Sell |
-30,000
| Closed | -$3.93M | – | 5580 |
|
|
2024
Q4 | $3.93M | Hold |
30,000
| – | – | ﹤0.01% | 2205 |
|
|
2024
Q3 | $4.67M | Hold |
30,000
| – | – | ﹤0.01% | 1908 |
|
|
2024
Q2 | $4.68M | Hold |
30,000
| – | – | ﹤0.01% | 1673 |
|
|
2024
Q1 | $4.07M | Buy |
+30,000
| New | +$3.97M | ﹤0.01% | 1869 |
|
|
2023
Q1 | – | Sell |
-15,000
| Closed | -$2.03M | – | 5493 |
|
|
2022
Q4 | $2.03M | Hold |
15,000
| – | – | ﹤0.01% | 2025 |
|
|
2022
Q3 | $1.65M | Hold |
15,000
| – | – | ﹤0.01% | 2301 |
|
|
2022
Q2 | $1.98M | Hold |
15,000
| – | – | ﹤0.01% | 2106 |
|
|
2022
Q1 | $1.99M | Sell |
15,000
-124,140
| -89% | -$14.9M | ﹤0.01% | 2358 |
|
|
2021
Q4 | $16.2M | Buy |
139,140
+47,500
| +52% | +$5.59M | 0.01% | 1128 |
|
|
2021
Q3 | $11M | Buy |
91,640
+46,640
| +104% | +$5.43M | 0.01% | 1346 |
|
|
2021
Q2 | $5.39M | Buy |
+45,000
| New | +$4.94M | ﹤0.01% | 1837 |
|
|
2021
Q1 | – | Sell |
-80,000
| Closed | -$8M | – | 6258 |
|
|
2020
Q4 | $8M | Buy |
80,000
+18,050
| +29% | +$1.91M | ﹤0.01% | 1749 |
|
|
2020
Q3 | $6.79M | Buy |
61,950
+39,350
| +174% | +$4.38M | ﹤0.01% | 1677 |
|
|
2020
Q2 | $2.39M | Sell |
22,600
-294,850
| -93% | -$30.5M | ﹤0.01% | 2614 |
|
|
2020
Q1 | $28.4M | Buy |
317,450
+254,600
| +405% | +$24M | 0.03% | 568 |
|
|
2019
Q4 | $6.27M | Sell |
62,850
-6,450
| -9% | -$607K | ﹤0.01% | 1847 |
|
|
2019
Q3 | $6.18M | Buy |
69,300
+15,900
| +30% | +$1.38M | ﹤0.01% | 1759 |
|
|
2019
Q2 | $4.41M | Buy |
53,400
+1,600
| +3% | +$125K | ﹤0.01% | 2067 |
|
|
2019
Q1 | $4.19M | Sell |
51,800
-113,550
| -69% | -$8.95M | ﹤0.01% | 1951 |
|
|
2018
Q4 | $12.6M | Buy |
165,350
+82,400
| +99% | +$6.43M | 0.01% | 1107 |
|
|
2018
Q3 | $6.57M | Buy |
82,950
+6,850
| +9% | +$518K | 0.01% | 1600 |
|
|
2018
Q2 | $5.34M | Sell |
76,100
-111,650
| -59% | -$8.03M | ﹤0.01% | 1775 |
|
|
2018
Q1 | $13.1M | Buy |
187,750
+27,900
| +17% | +$1.93M | 0.01% | 1050 |
|
|
2017
Q4 | $11.1M | Sell |
159,850
-84,650
| -35% | -$5.71M | 0.01% | 1218 |
|
|
2017
Q3 | $16.6M | Buy |
244,500
+129,600
| +113% | +$8.19M | 0.01% | 892 |
|
|
2017
Q2 | $7.83M | Buy |
114,900
+22,450
| +24% | +$1.47M | 0.01% | 1336 |
|
|
2017
Q1 | $5.76M | Sell |
92,450
-13,100
| -12% | -$763K | 0.01% | 1543 |
|
|
2016
Q4 | $5.77M | Buy |
105,550
+31,750
| +43% | +$1.8M | 0.01% | 1673 |
|
|
2016
Q3 | $4.85M | Buy |
73,800
+2,200
| +3% | +$144K | ﹤0.01% | 1698 |
|
|
2016
Q2 | $4.32M | Buy |
71,600
+9,800
| +16% | +$569K | ﹤0.01% | 1709 |
|
|
2016
Q1 | $3.48M | Sell |
61,800
-20,900
| -25% | -$1.26M | ﹤0.01% | 1897 |
|
|
2015
Q4 | $5.62M | Buy |
82,700
+11,200
| +16% | +$734K | 0.01% | 1594 |
|
|
2015
Q3 | $4.55M | Sell |
71,500
-83,200
| -54% | -$5.47M | ﹤0.01% | 1736 |
|
|
2015
Q2 | $9.86M | Buy |
154,700
+78,000
| +102% | +$5.34M | 0.01% | 1211 |
|
|
2015
Q1 | $5.25M | Sell |
76,700
-51,800
| -40% | -$3.6M | 0.01% | 1689 |
|
|
2014
Q4 | $9.04M | Sell |
128,500
-183,700
| -59% | -$13.2M | 0.01% | 1351 |
|
|
2014
Q3 | $22.3M | Sell |
312,200
-85,600
| -22% | -$6.27M | 0.02% | 733 |
|
|
2014
Q2 | $29.6M | Buy |
397,800
+274,200
| +222% | +$19.8M | 0.03% | 566 |
|
|
2014
Q1 | $8.02M | Sell |
123,600
-18,900
| -13% | -$1.22M | 0.01% | 1332 |
|
|
2013
Q4 | $8.46M | Buy |
142,500
+45,300
| +47% | +$2.46M | 0.01% | 1372 |
|
|
2013
Q3 | $5.05M | Sell |
97,200
-13,500
| -12% | -$678K | ﹤0.01% | 1744 |
|
|
2013
Q2 | $5.24M | Buy |
+110,700
| New | +$5.64M | 0.01% | 1593 |
|
Other funds holding AZN
IA
VCM
VAM
Citigroup's AZN Position: Q1 2026 in Review
Citigroup increased its AstraZeneca (AZN) stake by 20% in Q1 2026, buying an estimated $121M and bringing the position to 3,705,472 shares worth $718M. The position accounts for 0.31% of the portfolio, ranked #60.
Citigroup first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $720M in Q2 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Citigroup held 3,705,472 shares of AstraZeneca worth $718M as of Q1 2026.
- Citigroup bought 628,092 AstraZeneca shares in Q1 2026, an estimated $121M.
- AstraZeneca made up 0.31% of Citigroup's portfolio in Q1 2026, its #60 holding.
- Citigroup first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- Citigroup's AstraZeneca position peaked at $720M in Q2 2021.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.